Dermatology, MOHS-Micrographic Surgery · Twin Falls, ID
NPI
1245484096
Since 2008
Specialty
Dermatology, MOHS-Micrographic Surgery
Code 207ND0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
714 N College Rd, Suite A
Twin Falls, ID, 83301
Phone (208) 814-7180
Groups this clinician bills Medicare through
Medicare paid, 2024
$320K
5,600 services
Medicare patients, 2024
1,132
Average age 77
Drug cost, 2024
$400K
1,064 prescriptions
Company payments, 2023
$17.73
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kurtis B Reed was code 17003 (destruction skin lesion), 1,346 times for 287 patients. In total Kurtis B Reed billed 5,600 services in 87 codes, and Medicare paid $320K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-09-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,346 | 287 | $1.31 | $1,764 |
| 99213 Office E&M - Established | Office | 858 | 727 | $40.09 | $34K |
| 17311 Mohs Surgery | Office | 444 | 317 | $189.72 | $84K |
| 17000 Destruction Skin Lesion | Office | 395 | 362 | $32.84 | $13K |
| 11102 Skin Biopsy | Office | 390 | 323 | $17.96 | $7,005 |
| 88305 Surgical Pathology Examination | Office | 352 | 240 | $23.56 | $8,294 |
| 17312 Mohs Surgery | Office | 225 | 133 | $135.79 | $31K |
| 17004 Destruction Skin Lesion | Office | 187 | 156 | $60.35 | $11K |
| 99203 Office E&M - New | Office | 156 | 156 | $47.72 | $7,445 |
| 13132 Wound Repair - All Levels | Office | 156 | 148 | $110.22 | $17K |
| 17262 Destruction Skin Lesion | Office | 154 | 109 | $56.10 | $8,640 |
| 11103 Skin Biopsy | Office | 117 | 86 | $14.77 | $1,729 |
| 88331 Surgical Pathology Examination | Office | 109 | 85 | $41.18 | $4,489 |
| 99214 Office E&M - Established | Office | 103 | 93 | $57.90 | $5,964 |
| 13121 Wound Repair - All Levels | Office | 48 | 47 | $91.11 | $4,373 |
By year: 2022 $329K for 5,638 services; 2023 $330K for 5,567 services; 2024 $320K for 5,600 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 352 | 240 | $23.56 | $8,294 |
| 88331 Surgical Pathology Examination | 109 | 85 | $41.18 | $4,489 |
Medicare prescription drug claims, 2024
In 2024, the drug Kurtis B Reed prescribed most often to Medicare patients was Triamcinolone Acetonide, with 167 prescriptions and refills. In total Kurtis B Reed wrote 1,064 Medicare prescriptions that cost $400K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 167 | 218 | 99 | $1,535 |
| Fluocinonide Generic | 118 | 125 | 57 | $5,259 |
| Ketoconazole Generic | 80 | 88 | 35 | $932 |
| Clobetasol Propionate Generic | 59 | 63 | 27 | $2,751 |
| Cephalexin Generic | 49 | 49 | 45 | $304 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 48 | 48 | 29 | $942 |
| Hydroxyzine Hcl Generic | 44 | 62 | 17 | $404 |
| Metronidazole Generic | 43 | 44 | 25 | $2,815 |
| Methotrexate Methotrexate Sodium | 34 | 53 | 11 | $685 |
| Cosentyx (2 Syringes) Secukinumab | 31 | 31 | Under 11 | $241K |
| Fluorouracil Generic | 30 | 31 | 25 | $3,099 |
| Mometasone Furoate Generic | 26 | 27 | 13 | $477 |
| Prednisone Generic | 25 | 29 | 15 | $113 |
| Minocycline Hcl Generic | 21 | 21 | 15 | $390 |
| Gabapentin Generic | 19 | 36 | Under 11 | $407 |
Brand drugs: 85 claims; generic drugs: 979 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Kurtis B Reed $17.73 ($17.73 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $17.73.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $17.73 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.